(Q37638386)

English

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Chiara Napoletano

object named as

Chiara Napoletano

2

0 references

object named as

Ilary Ruscito

3

0 references

Filippo Bellati

object named as

Filippo Bellati

1

0 references

author name string

Maria Pastore

4

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Milena Pernice

5

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Morena Antonilli

6

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Marianna Nuti

7

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Pierluigi Benedetti Panici

8

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

publication date

24 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

887-894

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

https://scigraph.springernature.com/pub.10.1007/s10637-009-9351-4

0 references

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9351-4

21 January 2018

Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival of patients following secondary cytoreductive surgery in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-angiogenic therapies for metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological aspects of cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accumulation of selected carotenoids, alpha-tocopherol and retinol in human ovarian carcinoma ascitic fluid

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2008

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal interferon in the management of malignant ascites

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Malignant ascites: past, present, and future

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complications at the end of life in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palliation of malignant ascites

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model

1 reference

https://pubmed.ncbi.nlm.nih.gov/19936983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-009-9351-4

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37638386&oldid=1717182522"